Appeals Court Upholds PTAB's Finding Of Invalidity Of Purdue's 961 Patent
Portfolio Pulse from Bill Haddad
The Appeals Court has upheld the Patent Trial and Appeal Board's (PTAB) decision that Purdue Pharma's patent, number 961, is invalid. This ruling is a significant blow to Purdue Pharma, which has been embroiled in legal challenges over its patents.
November 27, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The upholding of the PTAB's finding of invalidity of Purdue's 961 patent may have implications for Collegium Pharmaceutical, Inc. (COLL), if they were involved in litigation or market competition related to this patent.
The article does not provide specific details on how the invalidation of Purdue's patent 961 directly affects Collegium Pharmaceutical, Inc. (COLL). However, if COLL was in direct competition or involved in litigation with Purdue regarding this patent, the ruling could potentially be beneficial for COLL by removing a barrier to market or ending costly litigation. Without specific details, the impact is considered neutral until further information is available.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50